The Korean Journal of Physiology and Pharmacology

The Korean Society of Pharmacology (대한약리학회)
권호 표지
DOI QR코드

DOI QR Code

Inhibition of chromosomal region maintenance 1 suppresses the migration and invasion of glioma cells via inactivation of the STAT3/MMP2 signaling pathway

  • Shan, Qianqian (Insititute of Nervous System Diseases, The Affiliated Hospital of Xuzhou Medical University, Xuzhou Medical University) ;
  • Li, Shengsheng (Insititute of Nervous System Diseases, The Affiliated Hospital of Xuzhou Medical University, Xuzhou Medical University) ;
  • Cao, Qiyu (Insititute of Nervous System Diseases, The Affiliated Hospital of Xuzhou Medical University, Xuzhou Medical University) ;
  • Yue, Chenglong (Insititute of Nervous System Diseases, The Affiliated Hospital of Xuzhou Medical University, Xuzhou Medical University) ;
  • Niu, Mingshan (Insititute of Nervous System Diseases, The Affiliated Hospital of Xuzhou Medical University, Xuzhou Medical University) ;
  • Chen, Xiangyu (Insititute of Nervous System Diseases, The Affiliated Hospital of Xuzhou Medical University, Xuzhou Medical University) ;
  • Shi, Lin (Insititute of Nervous System Diseases, The Affiliated Hospital of Xuzhou Medical University, Xuzhou Medical University) ;
  • Li, Huan (Insititute of Nervous System Diseases, The Affiliated Hospital of Xuzhou Medical University, Xuzhou Medical University) ;
  • Gao, Shangfeng (Insititute of Nervous System Diseases, The Affiliated Hospital of Xuzhou Medical University, Xuzhou Medical University) ;
  • Liang, Jun (Department of Neurosurgery, The Affiliated Hospital of Xuzhou Medical University) ;
  • Yu, Rutong (Insititute of Nervous System Diseases, The Affiliated Hospital of Xuzhou Medical University, Xuzhou Medical University) ;
  • Liu, Xuejiao (Insititute of Nervous System Diseases, The Affiliated Hospital of Xuzhou Medical University, Xuzhou Medical University)
  • Received : 2019.07.13
  • Accepted : 2019.12.20
  • Published : 2020.05.01
Download PDF
⟨ Previous Next ⟩

Abstract

Chromosomal region maintenance 1 (CRM1) is associated with an adverse prognosis in glioma. We previously reported that CRM1 inhibition suppressed glioma cell proliferation both in vitro and in vivo. In this study, we investigated the role of CRM1 in the migration and invasion of glioma cells. S109, a novel reversible selective inhibitor of CRM1, was used to treat Human glioma U87 and U251 cells. Cell migration and invasion were evaluated by wound-healing and transwell invasion assays. The results showed that S109 significantly inhibited the migration and invasion of U87 and U251 cells. However, mutation of Cys528 in CRM1 abolished the inhibitory activity of S109 in glioma cells. Furthermore, we found that S109 treatment decreased the expression level and activity of MMP2 and reduced the level of phosphorylated STAT3 but not total STAT3. Therefore, the inhibition of migration and invasion induced by S109 may be associated with the downregulation of MMP2 activity and expression, and inactivation of the STAT3 signaling pathway. These results support our previous conclusion that inhibition of CRM1 is an attractive strategy for the treatment of glioma.

Keywords

References

  1. Piromkraipak P, Sangpairoj K, Tirakotai W, Chaithirayanon K, Unchern S, Supavilai P, Power C, Vivithanaporn P. Cysteinyl leukotriene receptor antagonists inhibit migration, invasion, and expression of MMP-2/9 in human glioblastoma. Cell Mol Neurobiol. 2018;38:559-573. https://doi.org/10.1007/s10571-017-0507-z
  2. Mu N, Gu J, Liu N, Xue X, Shu Z, Zhang K, Huang T, Chu C, Zhang W, Gong L, Zhao H, Jia B, Gao D, Shang L, Zhang W, Guo Q. PRL-3 is a potential glioblastoma prognostic marker and promotes glioblastoma progression by enhancing MMP7 through the ERK and JNK pathways. Theranostics. 2018;8:1527-1539. https://doi.org/10.7150/thno.22699
  3. Liu YP, Dong FX, Chai X, Zhu S, Zhang BL, Gao DS. Role of autophagy in capsaicin-induced apoptosis in U251 glioma cells. Cell Mol Neurobiol. 2016;36:737-743. https://doi.org/10.1007/s10571-015-0254-y
  4. Zhang BL, Liu J, Lei Y, Xiong Y, Li H, Lin X, Yao RQ, Gao DS. An epigenetic mechanism of high gdnf transcription in glioma cells revealed by specific sequence methylation. Mol Neurobiol. 2016;53:4352-4362. https://doi.org/10.1007/s12035-015-9365-1
  5. Garcia-Santisteban I, Arregi I, Alonso-Marino M, Urbaneja MA, Garcia-Vallejo JJ, Banuelos S, Rodriguez JA. A cellular reporter to evaluate CRM1 nuclear export activity: functional analysis of the cancer-related mutant E571K. Cell Mol Life Sci. 2016;73:4685-4699. https://doi.org/10.1007/s00018-016-2292-0
  6. Noske A, Weichert W, Niesporek S, Roske A, Buckendahl AC, Koch I, Sehouli J, Dietel M, Denkert C. Expression of the nuclear export protein chromosomal region maintenance/exportin 1/Xpo1 is a prognostic factor in human ovarian cancer. Cancer. 2008;112:1733-1743. https://doi.org/10.1002/cncr.23354
  7. Tajiri N, De La Pena I, Acosta SA, Kaneko Y, Tamir S, Landesman Y, Carlson R, Shacham S, Borlongan CV. A nuclear attack on traumatic brain injury: sequestration of cell death in the nucleus. CNS Neurosci Ther. 2016;22:306-315. https://doi.org/10.1111/cns.12501
  8. Wang H, Ding Z, Shi QM, Ge X, Wang HX, Li MX, Chen G, Wang Q, Ju Q, Zhang JP, Zhang MR, Xu LC. Anti-androgenic mechanisms of Bisphenol A involve androgen receptor signaling pathway. Toxicology. 2017;387:10-16. https://doi.org/10.1016/j.tox.2017.06.007
  9. Zhou F, Chen E, You D, Song Y, Sun Z, Yue L. Both high expression of nucleophosmin/B23 and CRM1 predicts poorer prognosis in human gastric cancer. APMIS. 2016;124:1046-1053. https://doi.org/10.1111/apm.12604
  10. Li C, Yang D, Cao X, Wang F, Jiang H, Guo H, Du L, Guo Q, Yin X. LFG-500, a newly synthesized flavonoid, attenuates lipopolysaccharide-induced acute lung injury and inflammation in mice. Biochem Pharmacol. 2016;113:57-69. https://doi.org/10.1016/j.bcp.2016.05.007
  11. Yao Y, Dong Y, Lin F, Zhao H, Shen Z, Chen P, Sun YJ, Tang LN, Zheng SE. The expression of CRM1 is associated with prognosis in human osteosarcoma. Oncol Rep. 2009;21:229-235.
  12. Liu X, Chong Y, Tu Y, Liu N, Yue C, Qi Z, Liu H, Yao Y, Liu H, Gao S, Niu M, Yu R. CRM1/XPO1 is associated with clinical outcome in glioma and represents a therapeutic target by perturbing multiple core pathways. J Hematol Oncol. 2016;9:108. https://doi.org/10.1186/s13045-016-0338-2
  13. Yang X, Cheng L, Yao L, Ren H, Zhang S, Min X, Chen X, Zhang J, Li M. Involvement of chromosome region maintenance 1 (CRM1) in the formation and progression of esophageal squamous cell carcinoma. Med Oncol. 2014;31:155. https://doi.org/10.1007/s12032-014-0155-9
  14. Dickmanns A, Monecke T, Ficner R. Structural basis of targeting the exportin CRM1 in cancer. Cells. 2015;4:538-568. https://doi.org/10.3390/cells4030538
  15. Turner JG, Dawson J, Cubitt CL, Baz R, Sullivan DM. Inhibition of CRM1-dependent nuclear export sensitizes malignant cells to cytotoxic and targeted agents. Semin Cancer Biol. 2014;27:62-73. https://doi.org/10.1016/j.semcancer.2014.03.001
  16. Paulus A, Ailawadhi S, Chanan-Khan A. Novel therapeutic targets in Waldenstrom macroglobulinemia. Best Pract Res Clin Haematol. 2016;29:216-228. https://doi.org/10.1016/j.beha.2016.08.020
  17. Fathi N, Rashidi G, Khodadadi A, Shahi S, Sharifi S. STAT3 and apoptosis challenges in cancer. Int J Biol Macromol. 2018;117:993-1001. https://doi.org/10.1016/j.ijbiomac.2018.05.121
  18. Jiang C, Xu Q, Xu K, Dai H, Zhang Z, Wu W, Ni J. Effects of erythropoietin on STAT1 and STAT3 levels following cerebral ischemiareperfusion in rats. Int J Neurosci. 2013;123:684-690. https://doi.org/10.3109/00207454.2013.817409
  19. Zheng T, Hong X, Wang J, Pei T, Liang Y, Yin D, Song R, Song X, Lu Z, Qi S, Liu J, Sun B, Xie C, Pan S, Li Y, Luo X, Li S, Fang X, Bhatta N, Jiang H, et al. Gankyrin promotes tumor growth and metastasis through activation of IL-6/STAT3 signaling in human cholangiocarcinoma. Hepatology. 2014;59:935-946. https://doi.org/10.1002/hep.26705
  20. De Simone V, Franze E, Ronchetti G, Colantoni A, Fantini MC, Di Fusco D, Sica GS, Sileri P, MacDonald TT, Pallone F, Monteleone G, Stolfi C. Th17-type cytokines, IL-6 and TNF-$\alpha$ synergistically activate STAT3 and NF-kB to promote colorectal cancer cell growth. Oncogene. 2015;34:3493-3503. https://doi.org/10.1038/onc.2014.286
  21. Wang YC, Zheng LH, Ma BA, Zhou Y, Zhang MH, Zhang DZ, Fan QY. Clinical value of signal transducers and activators of transcription 3 (STAT3) gene expression in human osteosarcoma. Acta Histochem. 2011;113:402-408. https://doi.org/10.1016/j.acthis.2010.03.002
  22. Zhao C, Li H, Lin HJ, Yang S, Lin J, Liang G. Feedback activation of STAT3 as a cancer drug-resistance mechanism. Trends Pharmacol Sci. 2016;37:47-61. https://doi.org/10.1016/j.tips.2015.10.001
  23. Senft C, Priester M, Polacin M, Schroder K, Seifert V, Kogel D, Weissenberger J. Inhibition of the JAK-2/STAT3 signaling pathway impedes the migratory and invasive potential of human glioblastoma cells. J Neurooncol. 2011;101:393-403. https://doi.org/10.1007/s11060-010-0273-y
  24. Nusblat LM, Carroll MJ, Roth CM. Crosstalk between M2 macrophages and glioma stem cells. Cell Oncol (Dordr). 2017;40:471-482. https://doi.org/10.1007/s13402-017-0337-5
  25. Liu X, Chen X, Shi L, Shan Q, Cao Q, Yue C, Li H, Li S, Wang J, Gao S, Niu M, Yu R. The third-generation EGFR inhibitor AZD9291 overcomes primary resistance by continuously blocking ERK signaling in glioblastoma. J Exp Clin Cancer Res. 2019;38:219. https://doi.org/10.1186/s13046-019-1235-7
  26. Han ZX, Wang XX, Zhang SN, Wu JX, Qian HY, Wen YY, Tian H, Pei DS, Zheng JN. Downregulation of PAK5 inhibits glioma cell migration and invasion potentially through the PAK5-Egr1-MMP2 signaling pathway. Brain Tumor Pathol. 2014;31:234-241. https://doi.org/10.1007/s10014-013-0161-1
  27. Fan YC, Mei PJ, Chen C, Miao FA, Zhang H, Li ZL. MiR-29c inhibits glioma cell proliferation, migration, invasion and angiogenesis. J Neurooncol. 2013;115:179-188. https://doi.org/10.1007/s11060-013-1223-2
  28. Mei PJ, Bai J, Miao FA, Li ZL, Chen C, Zheng JN, Fan YC. Relationship between expression of XRCC1 and tumor proliferation, migration, invasion, and angiogenesis in glioma. Invest New Drugs. 2019;37:646-657. https://doi.org/10.1007/s10637-018-0667-9
  29. Yue C, Niu M, Shan QQ, Zhou T, Tu Y, Xie P, Hua L, Yu R, Liu X. High expression of Bruton's tyrosine kinase (BTK) is required for EGFR-induced NF-${\kappa}B$ activation and predicts poor prognosis in human glioma. J Exp Clin Cancer Res. 2017;36:132. https://doi.org/10.1186/s13046-017-0600-7
  30. Teng DC, Sun J, An YQ, Hu ZH, Liu P, Ma YC, Han B, Shi Y. Role of PHLPP1 in inflammation response: Its loss contributes to gliomas development and progression. Int Immunopharmacol. 2016;34:229-234. https://doi.org/10.1016/j.intimp.2016.02.034
  31. Liu F, Zhao X, Qian Y, Zhang J, Zhang Y, Yin R. MiR-206 inhibits Head and neck squamous cell carcinoma cell progression by targeting HDAC6 via PTEN/AKT/mTOR pathway. Biomed Pharmacother. 2017;96:229-237. https://doi.org/10.1016/j.biopha.2017.08.145
  32. Falk P, Jonsson A, Swartling T, Asplund D, Ivarsson ML. Role of matrix metalloproteinases in tumour invasion: immunohistochemistry of peritoneum from peritoneal carcinomatosis. Med Oncol. 2018;35:64. https://doi.org/10.1007/s12032-018-1122-7
  33. Yang Q, Wang WW, Ma P, Ma ZX, Hao M, Adelusi TI, Lei-Du, Yin XX, Lu Q. Swimming training alleviated insulin resistance through Wnt3a/$\beta$-catenin signaling in type 2 diabetic rats. Iran J Basic Med Sci. 2017;20:1220-1226.
  34. Chen F, Xu Y, Luo Y, Zheng D, Song Y, Yu K, Li H, Zhang L, Zhong W, Ji Y. Down-regulation of Stat3 decreases invasion activity and induces apoptosis of human glioma cells. J Mol Neurosci. 2010;40:353-359. https://doi.org/10.1007/s12031-009-9323-3
  35. Cho HJ, Park JH, Nam JH, Chang YC, Park B, Hoe HS. Ascochlorin suppresses MMP-2-mediated migration and invasion by targeting FAK and JAK-STAT signaling cascades. J Cell Biochem. 2018;119:300-313. https://doi.org/10.1002/jcb.26179
  36. Sun Q, Carrasco YP, Hu Y, Guo X, Mirzaei H, Macmillan J, Chook YM. Nuclear export inhibition through covalent conjugation and hydrolysis of Leptomycin B by CRM1. Proc Natl Acad Sci U S A. 2013;110:1303-1308. https://doi.org/10.1073/pnas.1217203110
  37. Lu DY, Yeh WL, Huang SM, Tang CH, Lin HY, Chou SJ. Osteopontin increases heme oxygenase-1 expression and subsequently induces cell migration and invasion in glioma cells. Neuro Oncol. 2012;14:1367-1378. https://doi.org/10.1093/neuonc/nos262
  38. Ishizawa J, Kojima K, Hail N Jr, Tabe Y, Andreeff M. Expression, function, and targeting of the nuclear exporter chromosome region maintenance 1 (CRM1) protein. Pharmacol Ther. 2015;153:25-35. https://doi.org/10.1016/j.pharmthera.2015.06.001
  39. Sakakibara K, Saito N, Sato T, Suzuki A, Hasegawa Y, Friedman JM, Kufe DW, Vonhoff DD, Iwami T, Kawabe T. CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity. Blood. 2011;118:3922-3931. https://doi.org/10.1182/blood.v118.21.3922.3922
  40. Li WX, Yang MX, Hong XQ, Dong TG, Yi T, Lin SL, Qin XY, Niu WX. Overexpression of gelsolin reduces the proliferation and invasion of colon carcinoma cells. Mol Med Rep. 2016;14:3059-3065. https://doi.org/10.3892/mmr.2016.5652
  41. Friedl P, Alexander S. Cancer invasion and the microenvironment: plasticity and reciprocity. Cell. 2011;147:992-1009. https://doi.org/10.1016/j.cell.2011.11.016
  42. Panth KM, van den Beucken T, Biemans R, Lieuwes NG, Weber M, Losen M, Yaromina A, Dubois LJ, Lambin P. In vivo optical imaging of MMP2 immuno protein antibody: tumor uptake is associated with MMP2 activity. Sci Rep. 2016;6:22198. https://doi.org/10.1038/srep22198
  43. Yu Q, Shen W, Zhou H, Dong W, Gao D. Knockdown of LIcadherin alters expression of matrix metalloproteinase-2 and -9 and galectin-3. Mol Med Rep. 2016;13:4469-4474. https://doi.org/10.3892/mmr.2016.5069
  44. Gravina GL, Tortoreto M, Mancini A, Addis A, Di Cesare E, Lenzi A, Landesman Y, McCauley D, Kauffman M, Shacham S, Zaffaroni N, Festuccia C. XPO1/CRM1-selective inhibitors of nuclear export (SINE) reduce tumor spreading and improve overall survival in preclinical models of prostate cancer (PCa). J Hematol Oncol. 2014;7:46. https://doi.org/10.1186/1756-8722-7-46
  45. Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol. 2007;7:41-51. https://doi.org/10.1038/nri1995
  46. Sato N, Tsuruma R, Imoto S, Sekine Y, Muromoto R, Sugiyama K, Matsuda T. Nuclear retention of STAT3 through the coiledcoil domain regulates its activity. Biochem Biophys Res Commun. 2005;336:617-624. https://doi.org/10.1016/j.bbrc.2005.08.145
  47. Ou Y, Liu L, Xue L, Zhou W, Zhao Z, Xu B, Song Y, Zhan Q. TRAP1 shows clinical significance and promotes cellular migration and invasion through STAT3/MMP2 pathway in human esophageal squamous cell cancer. J Genet Genomics. 2014;41:529-537. https://doi.org/10.1016/j.jgg.2014.08.004
  48. Herrmann A, Vogt M, Monnigmann M, Clahsen T, Sommer U, Haan S, Poli V, Heinrich PC, Muller-Newen G. Nucleocytoplasmic shuttling of persistently activated STAT3. J Cell Sci. 2007;120(Pt 18):3249-3261. https://doi.org/10.1242/jcs.03482
  49. Bhattacharya S, Schindler C. Regulation of Stat3 nuclear export. J Clin Invest. 2003;111:553-559. https://doi.org/10.1172/JCI15372
  50. Shao WY, Yang YL, Yan H, Huang Q, Liu KJ, Zhang S. Phenethyl isothiocyanate suppresses the metastasis of ovarian cancer associated with the inhibition of CRM1-mediated nuclear export and mTOR-STAT3 pathway. Cancer Biol Ther. 2017;18:26-35. https://doi.org/10.1080/15384047.2016.1264540
  51. Cheng Y, Holloway MP, Nguyen K, McCauley D, Landesman Y, Kauffman MG, Shacham S, Altura RA. XPO1 (CRM1) inhibition represses STAT3 activation to drive a survivin-dependent oncogenic switch in triple-negative breast cancer. Mol Cancer Ther. 2014;13:675-686. https://doi.org/10.1158/1535-7163.MCT-13-0416
  52. Xie TX, Wei D, Liu M, Gao AC, Ali-Osman F, Sawaya R, Huang S. Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis. Oncogene. 2004;23:3550-3560. https://doi.org/10.1038/sj.onc.1207383